目的:总结分析生物制剂在银屑病患者中的应用。
方法:依托2020年6月至2021年9月中国银屑病规范化诊疗中心数据库收集的数据,对中国188家三级医院2529例接受生物制剂治疗的银屑病患者进行回顾性分析。收集的信息主要包括人口统计数据(年龄,性别,银屑病病史),使用生物制品药物停药的疗效及其原因。根据收集到的信息,分析了各类生物制品的使用情况和生物制品替代的影响因素。
结果:共分析2529例患者,其中男性1626例(64.29%),女性903例(35.71%),平均年龄42.12±14.70(17~85)岁;年龄19~60岁2336例(92.37%)。在这些患者中,其中2362(93.40%)有银屑病面积和严重程度指数(PASI)评分,这些患者中有1776例中度至重度病例(75.19%)。根据患者对过去生物制剂疗效的自我评价,苏金单抗被大多数人选择疗效最高(1140例,93.60%)。苏金单抗停药的主要原因是停药时病情已经得到很好的控制(67例,38.95%);对于TNF-α抑制剂疗效较差;对于ustekinumab和ixekizumab是不可承受的价格。
结论:在目前中国银屑病的生物治疗中,苏金单抗的疗效被大多数人认为是最高的。当需要改变生物制剂时,Secukinumab是首选。
OBJECTIVE: To summarize and analysis the application of biologic agents in patients with psoriasis in the real world.
METHODS: Relying on collected data from June 2020 to September 2021 in the database of China Psoriasis Standardized Diagnosis and Treatment Center, 2529 cases of psoriasis patients treated with biologic agents in 188 different tertiary hospitals across China were retrospective analyzed. The collected information mainly includes demographic data (age, gender, psoriasis history), curative effectiveness of used biologics drug withdrawal and its reason. According to the collected information, condition of the usage for each category of biologics and influencing factor of biologics replacement were analyzed.
RESULTS: A total of 2529 patients were analyzed, which included 1626 male (64.29%) and 903 female (35.71%) with an average age of 42.12 ± 14.70 (17 ∼ 85) years old; 2336 (92.37%) patients were aged from 19 to 60 years old. Within these patients, 2362 of them (93.40%) had a psoriasis area and severity index (PASI) score, and 1776 of these patients had moderate to severe cases (75.19%). According to the patient\'s self-evaluation of the past efficacy of biological agents, secukinumab was chosen by the most people to have the highest efficacy (1140 cases, 93.60%). The main reason for the withdrawal of secukinumab is that the disease is already well controlled at the time of withdrawal (67 cases, 38.95%); for TNF- α inhibitor is the poor curative effect; for ustekinumab and ixekizumab were the non-affordable price.
CONCLUSIONS: In the current biotherapy of psoriasis in China, the efficacy of secukinumab is thought by most people to be the highest. Secukinumab is the first choice when the needs of changing biologics appear.